冠状动脉疾病
个性化医疗
代谢组学
疾病
医学
精密医学
生物标志物
生物信息学
药物开发
重症监护医学
药品
生物
内科学
药理学
病理
生物化学
出处
期刊:Advances in Clinical Chemistry
日期:2021-01-01
卷期号:: 233-270
被引量:5
标识
DOI:10.1016/bs.acc.2020.08.003
摘要
Coronary artery disease (CAD), the most common cardiovascular disease (CVD), contributes to significant mortality worldwide. CAD is a multifactorial disease wherein various factors contribute to its pathogenesis often complicating management. Biomarker based personalized medicine may provide a more effective way to individualize therapy in multifactorial diseases in general and CAD specifically. Systems' biology “Omics” biomarkers have been investigated for this purpose. These biomarkers provide a more comprehensive understanding on pathophysiology of the disease process and can help in identifying new therapeutic targets and tailoring therapy to achieve optimum outcome. Metabolomics biomarkers usually reflect genetic and non-genetic factors involved in the phenotype. Metabolomics analysis may provide better understanding of the disease pathogenesis and drug response variation. This will help in guiding therapy, particularly for multifactorial diseases such as CAD. In this chapter, advances in metabolomics analysis and its role in personalized medicine will be reviewed with comprehensive focus on CAD. Assessment of risk, diagnosis, complications, drug response and nutritional therapy will be discussed. Together, this chapter will review the current application of metabolomics in CAD management and highlight areas that warrant further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI